Systemic lupus erythematosus (SLE) is a systematic autoimmune inflammatory disease with a varying clinical manifestation, and its incidence is much higher in women than in men (>8:1).1, 2 In clinical practice, a first‐line therapy for SLE patients is long‐term use of glucocorticoids (GCs), which exert their biological effects after combining with glucocorticoid receptor (GR). The gene discussed is NR3C1; the disease is systemic lupus erythematosus.